Multiple Comparisons Procedures for Analyses of Joint Primary Endpoints and Secondary Endpoints
Pharmaceutical Statistics · 2025-05 · 24 (3)
DOI: 10.1002/pst.70010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 26.03.2025. Verfasst von Xiaolong Luo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biometrics, Sarepta Therapeutics, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Endpoint Determination, Research Design, Drug Development, Clinical Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
One of the main challenges in drug development for rare diseases is selecting the appropriate primary endpoints for pivotal studies. Although many endpoints can effectively reflect clinical benefit, their sensitivity often varies, making it difficult to determine the required sample size for study design and to interpret final results, which may be underpowered for some or all endpoints. This complexity is further compounded when there is a desire to support regulatory claims for multiple clinical endpoints and dose regimens due to the issues of multiplicity and sample size constraints. Joint Primary Endpoints (JPEs) offer a compelling strategy to address these challenges; however, their analysis in conjunction with component endpoints presents additional complexities, particularly in managing multiplicity concerns for regulatory claims. To address these issues, this paper introduces a robust two‐stage gatekeeping framework designed to test two hierarchically ordered families of hypotheses. A novel truncated closed testing procedure is employed in the first stage, enhancing flexibility and adaptability in the evaluation of primary endpoints. This approach strategically propagates a controlled fraction of the error rate to the second stage for assessing secondary endpoints, ensuring rigorous control of the global family‐wise Type I error rate across both stages. Through extensive numerical simulations and real‐world clinical trial applications, we demonstrate the efficiency, adaptability, and practical utility of this approach in advancing drug development for rare diseases while meeting stringent regulatory requirements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biometrics, Sarepta Therapeutics, Cambridge, Massachusetts, USA.
- Department of Mathematical Sciences, New Jersey Institute of Technology, University Heights, Newark, New Jersey, USA.
ORCID-Profile: Xiaolong Luo, Xiao Ni
Zitieren
APA
Luo, X., Li, L., Savenkov, O., Liu, W., Ni, X., Tang, W., & Guo, W. (2025). Multiple Comparisons Procedures for Analyses of Joint Primary Endpoints and Secondary Endpoints. Pharmaceutical Statistics, 24(3). https://doi.org/10.1002/pst.70010
Vancouver
Luo X, Li L, Savenkov O, Liu W, Ni X, Tang W, et al. Multiple Comparisons Procedures for Analyses of Joint Primary Endpoints and Secondary Endpoints. Pharmaceutical Statistics. 2025;24(3). doi:10.1002/pst.70010
BibTeX
@article{Luo2025,
author = {Luo, Xiaolong and Li, Lerong and Savenkov, Oleksandr and Liu, Weijian and Ni, Xiao and Tang, Weihua and Guo, Wenge},
title = {Multiple Comparisons Procedures for Analyses of Joint Primary Endpoints and Secondary Endpoints},
journal = {Pharmaceutical Statistics},
year = {2025},
volume = {24},
number = {3},
doi = {10.1002/pst.70010}
}
EUVIMED